
NICE (National Institute for Health and Care Excellence)
9.0K subscribers
Verified ChannelAbout NICE (National Institute for Health and Care Excellence)
Follow for the latest info on NICE guidelines and drug recommendations.
Similar Channels
Swipe to see more
Posts

‘Artificial pancreas’ transforming the lives of thousands of children and young people with type 1 diabetes. Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology known as a hybrid closed loop system, recommended by NICE. Learn more in our data story: https://www.nice.org.uk/news/articles/-artificial-pancreas-transforming-lives-of-thousands-of-children-and-young-people-with-type-1-diabetes?utm_medium=organic&utm_source=whatsapp&utm_campaign=hcl_data_story&utm_content=graphic


The first-ever targeted treatment for generalised pustular psoriasis has been recommended by NICE. Learn how spesolimab can treat severe flares of this rare, life-threatening skin condition⤵️ https://www.nice.org.uk/guidance/ta1070/chapter/1-recommendations?utm_medium=organic&utm_source=whatsapp&utm_campaign=gpp_flares&utm_content=finalvideo

📢Our updated technology evaluation methods will help tackle health inequalities across communities. Read how NICE is ensuring fairer health outcomes in our blog post: https://www.nice.org.uk/news/blogs/health-inequalities-an-update-to-nice-s-methods-for-health-technology-evaluation?utm_medium=organic&utm_source=whatsapp&utm_campaign=hi_blogpost_140525&utm_content=graphic


🆕 breast cancer treatment recommended Our final guidance recommending capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment has been published today. Read the guidance here: https://www.nice.org.uk/guidance/ta1063?utm_medium=organic&utm_source=whatsapp&utm_campaign=capivasertib_150525&utm_content=quotegraphic


🆕Endometrial cancer treatment recommended by NICE Dostarlimab, recommended in final guidance, is set to benefit around 570 people with certain types of primary advanced or recurrent endometrial cancer. Clinical trials show that adding dostarlimab to standard chemotherapy helps women stay well longer⤵️ https://www.nice.org.uk/guidance/ta1064?utm_medium=organic&utm_source=whatsapp&utm_campaign=dostarlimab_220525&utm_content=finalvideo

🆕targeted combination treatment for advanced bowel cancer. Nivolumab with ipilimumab has been recommended in final guidance today. Find out more⤵️ https://www.nice.org.uk/guidance/ta1065?utm_medium=organic&utm_source=whatsapp&utm_campaign=nivolumab_with_ipilimumab_280525&utm_content=finalvideo

🆕Eczema treatment recommended by NICE People with moderate to severe eczema could be set to benefit after a new treatment option was recommended today. Find out more about Nemolizumab: https://nice.org.uk/guidance/indevelopment/gid-ta11183/documents?utm_medium=organic&utm_source=whatsapp&utm_campaign=nemolizumab_120625&utm_content=graphic…


🆕Weekly haemophilia B treatment approved by NICE NICE recommends marstacimab as the first once-weekly subcutaneous (under the skin) injection for people aged 12+ with severe haemophilia B. This replaces factor 9 replacement therapy, often requiring infusions every few days⤵️ https://www.nice.org.uk/news/articles/new-weekly-treatment-option-approved-for-people-with-haemophilia-b?utm_medium=organic&utm_source=whatsapp&utm_campaign=haem_b&utm_content=graphic


🎧Navigating the future - AI at NICE Join NICE's Dr Pall Jonnson and Dr Stephen Duffield as they explore the future of artificial intelligence in healthcare and evidence evaluation in our latest episode of NICE Talks. Listen now⤵️ https://soundcloud.com/nicecomms/02_2025_nice_and_ai_mixdown/s-f9SDrDcrQle

🩸Sickle cell disease treatment recommended in NICE final guidance. Following our recent draft guidance recommending innovative new treatment exa-cel for treating severe sickle cell disease, we are pleased to share this has now been confirmed in our final guidance published today⤵️ https://www.nice.org.uk/guidance/ta1044?utm_medium=organic&utm_source=whatsapp&utm_campaign=exacel_scd&utm_content=graphic